uracil has been researched along with Atherogenesis in 8 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM)." | 9.22 | Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). ( Gosho, M; Jinnouchi, H; Kaneto, H; Katakami, N; Kosugi, K; Kuribayashi, N; Mita, T; Onuma, T; Osonoi, T; Shimomura, I; Shiraiwa, T; Umayahara, Y; Watada, H; Yamamoto, T; Yokoyama, H; Yoshii, H, 2016) |
| "The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) is a prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study." | 9.17 | Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). ( Gosho, M; Jinnouchi, H; Kaneto, H; Katakami, N; Kosugi, K; Kuribayashi, N; Mita, T; Onuma, T; Osonoi, T; Shimomura, I; Shiraiwa, T; Umayahara, Y; Watada, H; Yamamoto, T; Yokoyama, H; Yoshii, H, 2013) |
| " The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM)." | 5.22 | Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). ( Gosho, M; Jinnouchi, H; Kaneto, H; Katakami, N; Kosugi, K; Kuribayashi, N; Mita, T; Onuma, T; Osonoi, T; Shimomura, I; Shiraiwa, T; Umayahara, Y; Watada, H; Yamamoto, T; Yokoyama, H; Yoshii, H, 2016) |
| "The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) is a prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study." | 5.17 | Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). ( Gosho, M; Jinnouchi, H; Kaneto, H; Katakami, N; Kosugi, K; Kuribayashi, N; Mita, T; Onuma, T; Osonoi, T; Shimomura, I; Shiraiwa, T; Umayahara, Y; Watada, H; Yamamoto, T; Yokoyama, H; Yoshii, H, 2013) |
| "Treatment naïve subjects with type 2 diabetes received 12." | 2.80 | Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties. ( Hirate, M; Kaneoka, N; Kutoh, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katakami, N | 2 |
| Mita, T | 2 |
| Yoshii, H | 2 |
| Onuma, T | 2 |
| Kaneto, H | 2 |
| Osonoi, T | 2 |
| Shiraiwa, T | 2 |
| Kosugi, K | 2 |
| Umayahara, Y | 2 |
| Yamamoto, T | 2 |
| Yokoyama, H | 2 |
| Kuribayashi, N | 2 |
| Jinnouchi, H | 2 |
| Gosho, M | 2 |
| Watada, H | 2 |
| Shimomura, I | 2 |
| Kutoh, E | 1 |
| Kaneoka, N | 1 |
| Hirate, M | 1 |
| Akita, K | 1 |
| Isoda, K | 1 |
| Shimada, K | 1 |
| Daida, H | 1 |
| Ta, NN | 1 |
| Schuyler, CA | 1 |
| Li, Y | 1 |
| Lopes-Virella, MF | 1 |
| Huang, Y | 1 |
| Shah, Z | 1 |
| Kampfrath, T | 1 |
| Deiuliis, JA | 1 |
| Zhong, J | 1 |
| Pineda, C | 1 |
| Ying, Z | 1 |
| Xu, X | 1 |
| Lu, B | 1 |
| Moffatt-Bruce, S | 1 |
| Durairaj, R | 1 |
| Sun, Q | 1 |
| Mihai, G | 1 |
| Maiseyeu, A | 1 |
| Rajagopalan, S | 1 |
| FILLIOS, LC | 1 |
| NAITO, C | 1 |
| ANDRUS, SB | 1 |
| ROACH, AM | 1 |
| Takeshita, J | 1 |
| Byun, J | 1 |
| Nhan, TQ | 1 |
| Pritchard, DK | 1 |
| Pennathur, S | 1 |
| Schwartz, SM | 1 |
| Chait, A | 1 |
| Heinecke, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for uracil and Atherogenesis
5 other studies available for uracil and Atherogenesis
| Article | Year |
|---|---|
Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice.
Topics: Actins; Animals; Anti-Inflammatory Agents; Arteritis; Atherosclerosis; Biomarkers; Blood Glucose; Ce | 2015 |
DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experime | 2011 |
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cell Movement; Chemotaxis; Dipeptidyl-P | 2011 |
Further studies on experimental atherosclerosis and dietary pyrimidines: orotic acid, thiouracil, and uracil in male and female rats.
Topics: Animals; Atherosclerosis; Diet; Female; Male; Orotic Acid; Pyrimidines; Rats; Thiouracil; Uracil | 1960 |
Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue: a potential pathway for somatic mutagenesis by macrophages.
Topics: Antioxidants; Aorta; Atherosclerosis; Chlorides; Chromatography, High Pressure Liquid; DNA; Dose-Res | 2006 |